CA-125 (Serum) – Tumor Marker for Ovarian Cancer Screening
This blood test measures a protein (CA-125) that may be elevated in certain cancers, including ovarian cancer, and sometimes in other conditions affecting the ovaries, uterus, or peritoneum.
["CA-125 helps monitor cancer progression or response to treatment but is not a definitive diagnostic test alone."]
Key facts at a glance
- LOINC
- 10334-1
- Short code
- CA125
- Synonyms
- Cancer Ag125 SerPl-aCnc
- Category
- chemistry
- Sample
- serum
- Container
- Serum separator tube (SST) or red-top tube; plasma may be collected in heparin or EDTA tubes
- Units
- N/A
- Ref low
- 0
- Ref high
- 35
- Critical range
- 0.5 N/A – —
- Fasting
- false
- Population
- adult
- Sex
- female
- Age range
- ≥ 18 years
- Method
- Immunoassay (chemiluminescent or electrochemiluminescent)
- CPT
- 86304
- SNOMED
- 1152695009
- Specimen volume
- 1 mL serum or plasma
- Stability
- Stable for 24 hours at room temperature (15-25°C), 7 days refrigerated (2-8°C), and 3 months frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 25
- TAT
- 4–24 hours
- Order
- routine
What Is CA-125 Used For?
CA-125 is primarily used as a screening or monitoring tool for ovarian cancer and sometimes in other gynecologic cancers. It may also help track how a cancer is responding to treatment or detect recurrence. However, it is not a standalone test for diagnosing ovarian cancer, as other conditions can also raise its levels.
How Is the Test Performed?
A small blood sample is drawn from a vein, usually in your arm. The blood is sent to a lab where it is tested for the CA-125 protein using an immunoassay method. Results are reported in units per liter (U/L).
When Might You Need This Test?
Your healthcare provider may order a CA-125 test if you have symptoms like abdominal pain, bloating, or changes in bowel habits. It may also be used in screening high-risk individuals (e.g., those with a family history of ovarian cancer) or as part of follow-up for ovarian cancer patients.
What Do Results Mean?
Elevated CA-125 levels may indicate ovarian cancer or other conditions like endometriosis, pelvic inflammatory disease, or liver disease. However, a normal result does not rule out ovarian cancer. Interpretation depends on clinical context, including symptoms, medical history, and imaging results.
Reference range
Normal: <35 U/mL. Values may vary by laboratory methodology and reference population.N/A
No special preparation required. Specimen collection is not affected by recent food intake or fasting status.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
Clinical Significance: CA-125 plays a key role in ovarian cancer surveillance but lacks specificity. It is often used alongside other tests (e.g., ultrasound, CA-125 screening algorithms) for better accuracy. False positives and negatives can occur, so results should be reviewed by a healthcare provider.
Short name
CA-125
Frequently asked questions
Why might my CA-125 test be ordered if I don’t have symptoms?
Can CA-125 levels change over time, and what does that mean?
Are there any side effects or risks from this blood test?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 17, 2026. · Read our editorial policy